Addex Therapeutics Ltd

NASDAQ: ADXN · Real-Time Price · USD
8.07
-0.50 (-5.86%)
At close: May 02, 2025, 3:24 PM
8.07
0.00%
After-hours: May 02, 2025, 04:00 PM EDT
-5.86%
Bid 7.05
Market Cap 6.61M
Revenue (ttm) 557.48K
Net Income (ttm) 5.4M
EPS (ttm) -23.31
PE Ratio (ttm) -0.35
Forward PE -1.53
Analyst Buy
Ask 9.2
Volume 1,295
Avg. Volume (20D) 7,579
Open 8.07
Previous Close 8.57
Day's Range 8.07 - 8.07
52-Week Range 6.51 - 13.27
Beta 1.97

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX7...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2020
Employees 23
Stock Exchange NASDAQ
Ticker Symbol ADXN
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for ADXN stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 271.75% from the latest price.

Stock Forecasts
5 months ago
-18.65%
Addex Therapeutics shares are trading lower. The c... Unlock content with Pro Subscription
7 months ago
+7.96%
Addex Therapeutics shares are trading higher after the company reported H2 financial results.